Clinical Trial Update: Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2) [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluating Eryaspase in combination with chemotherapy versus chemotherapy alone for triple negative breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• Eryaspase (pegylated asparaginase)

Snippet

Sponsor: ERYtech Pharma | Conditions: Triple Negative Breast Cancer | Phase 2, Phase 3 | Status: TERMINATED